The news that the Johnson & Johnson (JNJ.US) vaccine would be paused appeared to be beneficial for Moderna (MRNA.US) which shares gained more than 7% following FDA announcement. The drugmaker has also issued a statement saying that data indicates its COVID-19 vaccine is not associated with cerebral venous sinus thrombosis ("CVST") or other thrombotic events. Moderna announced that assessment was made based on safety data through March 22 of more than 64.5M doses administered worldwide.
Moderna (MRNA.US) stock launched today's session with a bullish price gap and is currently testing the upper limit of the descending channel which coincides with 50 SMA (green line). Source: xStation5
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appThis content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
